
Microfluidics Manufacture of Verteporfin Loaded Liposomes Composed of Natural and Synthetic Lipids Using a Scalable Microfludic Platform

Andrew Brown, Mark Ma, Ben Versteeg, Richard Broadhead, Shell Ip, Anitha Thomas, Tim Leaver, Euan Ramsay
Precision NanoSystems Inc., Vancouver, BC, V6P 6T7, Canada

Abstract (300 word limit)

Liposomes are attractive drug delivery systems for formulating low solubility drugs. While several liposomal drugs are presently marketed, liposome production is commonly a multi-step processes that requires significant process development to scale up production through preclinical and clinical development. Here, we leverage the reproducible, continuous flow nature of a microfluidic platform to control the nanoprecipitation of liposomes, rapidly tune liposome size and drug loading, and reduce process development associated with increasing scale of production. Two liposome formulations of the hydrophobic photosensitizer verteporfin were produced as model systems and scaled up in batch volume by an order of magnitude. A process for liposome formation and simultaneous drug loading was initially developed at bench scale, on a system designed for rapid formulation optimization at volumes between 1 mL and 15mL. A Soy-PC/cholesterol/DSPE-PEG formulation was optimized by systematically varying the flow rate ratio between the aqueous and organic phases at the input of the microfluidic mixer, and their total follow rate. Optimized formulation parameters were also used to produce a DMPC/Egg-PG formulation the more closely resembles commercially available formulations. Both formulations were transferred directly to a larger system designed for producing pre-clinical batches between 10mL and 1000mL. As a consequence of conserved microfluidic geometry between the two systems, formulation conditions were replicated exactly. Hence, the physical characteristics and encapsulation efficiency were found to be identical between formulations produced on the two systems. This reduces the burden of process development commonly encountered when scaling up traditional liposome production methods.



Biography (150 word limit)

Tim Leaver is the Director of Product Management and Commercialization at Precision NanoSystems. With over ten years of experience developing automation and microfluidic products and solutions in life sciences fields, he has worked on problems ranging from drug delivery to single cell genomics. He studied at the University of British Columbia in the field of Engineering Physics.

Email: tleaver@precision-nano.com

Notes/Comments: